Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	7/17/2001 11:54:11 AM
From: nigel bates	of 253

SAN CARLOS, Calif.--(BW HealthWire)--July 17, 2001--Neugenesis Corporation and Genencor International today announced the initiation of the second phase of a collaborative research and development project designed to improve an important industrial enzyme. This project couples Neugenesis' proprietary directed evolution technologies with Genencor's exceptional platforms for screening improved enzyme activities for diversity in fungal genes in order to generate and identify more robust and useful products. ``This collaborative project with Genencor International provides significant third party validation for the potential of our emerging technology in the area of directed evolution,'' said Neugenesis President and CEO, W. Dorsey Stuart. ``Neugenesis has key patent filings on these technologies developed by CSO Edward Cambareri and on synergistic technology developed by consultant David Catcheside. Early results support our confidence in the broad applicability and usefulness of these platforms.'' ``As the industry leader in directed molecular evolution, we constantly look for new tools through collaborations to bring a product to market quickly and efficiently,'' said Michael V. Arbige, senior vice president, Technology for Genencor. ``We look forward to the opportunities generated by this collaboration with Neugenesis.'' Neugenesis Corporation is a privately held biotechnology company focused on generation of diversity of single gene products and multi-gene pathways. Neugenesis holds a strong intellectual property position in the areas of in vivo gene diversification and in vivo combinatorial biology. Both platforms are synergistically coupled to protein expression for direct readout of altered properties of newly created proteins including enzymes involved in small molecule synthesis. Thus the Neugenesis technology platforms have applications across a wide range of biotechnology products from small molecule drug discovery through new and improved biopharmaceuticals... For further information contact neugenesis.com Also, see - Message 15869597

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next